/
Invest New Drugs
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
- F. Kroschinsky
- J.M. Middeke
- M. Janz
- G. Lenz
- M. Witzens-Harig
- R. Bouabdallah
- P. La Rosée
- A. Viardot
- G. Salles
- S.J. Kim
- T.M. Kim
- O. Ottmann
- J. Chromik
- A.M. Quinson
- U. von Wangenheim
- U. Burkard
- A. Berk
- N. Schmitz